Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports

RATIONALE: Most of nonsmall cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) activating mutations eventually acquire resistance to the first EGFR-tyrosine kinase inhibitors (TKIs) therapy after varying periods of treatment. Of note, approximately one-third of those...

Descripción completa

Detalles Bibliográficos
Autores principales: Koba, Taro, Kijima, Takashi, Takimoto, Takayuki, Hirata, Haruhiko, Naito, Yujiro, Hamaguchi, Masanari, Otsuka, Tomoyuki, Kuroyama, Muneyoshi, Nagatomo, Izumi, Takeda, Yoshito, Kida, Hiroshi, Kumanogoh, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313025/
https://www.ncbi.nlm.nih.gov/pubmed/28178168
http://dx.doi.org/10.1097/MD.0000000000006087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313025/
https://www.ncbi.nlm.nih.gov/pubmed/28178168
http://dx.doi.org/10.1097/MD.0000000000006087

Ejemplares similares